CA2998275A1 - In vitro method for identifying a pregnancy related disease - Google Patents
In vitro method for identifying a pregnancy related disease Download PDFInfo
- Publication number
- CA2998275A1 CA2998275A1 CA2998275A CA2998275A CA2998275A1 CA 2998275 A1 CA2998275 A1 CA 2998275A1 CA 2998275 A CA2998275 A CA 2998275A CA 2998275 A CA2998275 A CA 2998275A CA 2998275 A1 CA2998275 A1 CA 2998275A1
- Authority
- CA
- Canada
- Prior art keywords
- plgf
- sflt
- plap
- glycemia
- diabetes mellitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217270P | 2015-09-11 | 2015-09-11 | |
| US62/217,270 | 2015-09-11 | ||
| EP16161490.4 | 2016-03-21 | ||
| EP16161490 | 2016-03-21 | ||
| PCT/IB2016/055426 WO2017042751A1 (en) | 2015-09-11 | 2016-09-12 | In vitro method for identifying a pregnancy related disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2998275A1 true CA2998275A1 (en) | 2017-03-16 |
Family
ID=55646323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2998275A Abandoned CA2998275A1 (en) | 2015-09-11 | 2016-09-12 | In vitro method for identifying a pregnancy related disease |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11009512B2 (enExample) |
| EP (2) | EP3502705B1 (enExample) |
| JP (1) | JP2018536170A (enExample) |
| CN (1) | CN108700591A (enExample) |
| AU (1) | AU2016319010A1 (enExample) |
| CA (1) | CA2998275A1 (enExample) |
| WO (1) | WO2017042751A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200264188A1 (en) | 2017-09-13 | 2020-08-20 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
| GB2612911B (en) * | 2019-02-14 | 2023-11-22 | Mirvie Inc | Methods and systems for determining a pregnancy-related state of a subject |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN113308533B (zh) * | 2021-05-31 | 2023-10-24 | 东莞市人民医院 | 妊娠期糖尿病患者胎盘来源外泌体miRNA表达分析方法 |
| GB202219102D0 (en) * | 2022-12-16 | 2023-02-01 | Univ Oxford Innovation Ltd | Method |
| CN117647653B (zh) * | 2023-12-22 | 2024-05-07 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 一种与子痫前期相关的生物标志物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005017192A2 (en) * | 2003-08-14 | 2005-02-24 | The General Hospital Corporation | Screening for gestational disorders |
| JP5009811B2 (ja) * | 2004-12-21 | 2012-08-22 | イェール ユニバーシティ | 子癇前症の検出 |
| US20070218519A1 (en) | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
| CN101563597A (zh) * | 2006-09-01 | 2009-10-21 | 美国菌种保藏中心 | 用于诊断和治疗2型糖尿病的组合物和方法 |
| US20080300170A1 (en) * | 2006-09-01 | 2008-12-04 | Cohava Gelber | Compositions and methods for diagnosis and treatment for type 2 diabetes |
| JP2013509587A (ja) * | 2009-10-29 | 2013-03-14 | テシス バイオサイエンス， インコーポレイテッド | 糖尿病のリスクを決定する方法 |
| US10054599B2 (en) * | 2013-03-12 | 2018-08-21 | Agency For Science, Technology And Research (A*Star) | Pre-eclampsia biomarkers |
-
2016
- 2016-09-12 AU AU2016319010A patent/AU2016319010A1/en not_active Abandoned
- 2016-09-12 WO PCT/IB2016/055426 patent/WO2017042751A1/en not_active Ceased
- 2016-09-12 JP JP2018532841A patent/JP2018536170A/ja active Pending
- 2016-09-12 CA CA2998275A patent/CA2998275A1/en not_active Abandoned
- 2016-09-12 EP EP19153119.3A patent/EP3502705B1/en active Active
- 2016-09-12 US US15/758,706 patent/US11009512B2/en active Active
- 2016-09-12 EP EP16766645.2A patent/EP3347719B1/en active Active
- 2016-09-12 CN CN201680066289.4A patent/CN108700591A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018536170A (ja) | 2018-12-06 |
| AU2016319010A1 (en) | 2018-04-12 |
| EP3502705B1 (en) | 2020-09-09 |
| EP3502705A1 (en) | 2019-06-26 |
| US20180259534A1 (en) | 2018-09-13 |
| WO2017042751A1 (en) | 2017-03-16 |
| EP3347719A1 (en) | 2018-07-18 |
| EP3347719B1 (en) | 2019-07-10 |
| AU2016319010A8 (en) | 2018-04-26 |
| CN108700591A (zh) | 2018-10-23 |
| US11009512B2 (en) | 2021-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2998275A1 (en) | In vitro method for identifying a pregnancy related disease | |
| Caillon et al. | Evaluation of sFlt-1/PlGF ratio for predicting and improving clinical management of pre-eclampsia: experience in a specialized perinatal care center. | |
| Levine et al. | Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia | |
| Sorensen et al. | Elevated second-trimester serum homocyst (e) ine levels and subsequent risk of preeclampsia | |
| Chaparro et al. | Placental biomarkers and angiogenic factors in oral fluids of patients with preeclampsia | |
| Perini et al. | Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery disease | |
| US20190145967A1 (en) | Index of local severity of atopic dermatitis in skin and therapeutic effect thereon | |
| ES2543171T3 (es) | HbF y A1M como marcadores de fase inicial para preeclampsia | |
| US11035864B2 (en) | In vitro method for identifying a pregnancy related disease | |
| AU2018228279B2 (en) | Markers of tissue aging and uses therefor | |
| RU2453851C1 (ru) | Способ прогнозирования степени эффективности снижения тяжести проявлений атопического дерматита | |
| EP3058371B1 (en) | Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd | |
| Bayram et al. | The effect of maternal serum sFAS/sFASL system on etiopathogenesis of preeclampsia and severe preeclampsia | |
| RU2688209C1 (ru) | Способ прогнозирования характера течения изолированной формы акантолитической пузырчатки полости рта | |
| US20240016804A1 (en) | Methods and materials for assessing and treating hypertensive disorders | |
| Amin et al. | Evaluation of Podocalyxin level in pre-eclampsia with severe features' patients: a cross-sectional study | |
| Rahamon et al. | Cellular inflammatory markers and Castelli risk indices in women with gestational diabetes mellitus | |
| Granger et al. | for Huntington's Disease Biomarker | |
| AU2014337504A1 (en) | Use of acamprosate to modulate ERK 1-2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD | |
| Farhan | Mean platelet volume and platelet distribution width as predictors for preterm labour | |
| RU2388413C1 (ru) | Способ оценки степени тяжести трофологической недостаточности у больных хронической обструктивной болезнью легких | |
| RU2294202C1 (ru) | Способ выбора индивидуального лечения больных бронхиальной астмой | |
| RU2316006C1 (ru) | Способ оценки характера течения пузырчатки | |
| Widiyanti et al. | High urine sodium/potassium ratio, high LDL/HDL ratio, high level of serum F2-isoprostane, and low level of microtubule-associated protein 1a/1b-light chain 3b (LC3B) as risk factors of preeclampsia | |
| RU2276367C1 (ru) | Способ прогнозирования развития ранней плацентарной недостаточности в предгравидарный период |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220315 |
|
| FZDE | Discontinued |
Effective date: 20220315 |